earnings
confidence high
sentiment positive
materiality 0.70
Armata Q3 loss from ops $7.8M; AP-SA02 Phase 2a shows efficacy, cGMP facility commissioned
Armata Pharmaceuticals, Inc.
2025-Q3 EPS
reported -$1.37
vs consensus -$0.43
▼ miss
(-219.8%)
- Q3 2025 grant revenue $1.2M (vs $3.0M prior year); R&D expense $5.8M (vs $9.5M).
- Loss from operations $7.8M (vs $9.8M prior year); cash $14.8M as of Sep 30, 2025.
- Phase 2a diSArm study: AP-SA02 + BAT had higher cure rate at day 12 vs BAT alone; 100% response without relapse.
- 56,000 sq ft cGMP manufacturing facility in Los Angeles fully commissioned; enables scale-up for late-stage trials.
- Entered $15M secured credit agreement with Innoviva subsidiary, maturing January 2029, to fund AP-SA02 development.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.